『Peptides Weekly』のカバーアート

Peptides Weekly

Peptides Weekly

著者： Patrick · Nerra Network
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
What peptides are, what the evidence actually shows, and what is approved, investigational or unregulated. Every Thursday: the week in peptide science and regulation, and one peptide explained properly — mechanism, studies, status, risks. Education only; never dosing, sourcing or protocols, and never medical advice. AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production.Copyright 2026 生物科学 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Ep 5: Three to four extra rare vision-loss cases per ten thousand showed up in an observational…

    Ep 5: Three to four extra rare vision-loss cases per ten thousand showed up in an observational…
    2026/10/15
    Peptides Weekly Three to four extra rare vision-loss cases per ten thousand showed up in an observational GLP-1 study. What You Need to Know: Three to four extra rare vision-loss cases per ten thousand showed up in an observational GLP-1 study. The link was seen in adults with type 2 diabetes and does not prove the drugs injured the optic nerve. ... Sources: ua.news · sciencedaily.com · biospace.com · medicaldaily.com · bipc.com · komu.com AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. If this episode was useful, a rating or a short review on Apple Podcasts or Spotify is how the next listener finds the show — and following it in your app means the next episode is there when you are. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.
    続きを読む 一部表示
    10 分
  • Ep 4: Unapproved peptides could reach temporary sale while treatment claims are still not fully…

    Ep 4: Unapproved peptides could reach temporary sale while treatment claims are still not fully…
    2026/10/08
    Peptides Weekly Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. What You Need to Know: Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. Political Wire, quoting The Washington Post, describes a drafting process for previously restricted peptides, not a completed approval and not a patient trial. ... Sources: washingtonpost.com · stocktwits.com · ascopost.com · amp.sacbee.com · foodnavigator.com AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. If this episode was useful, a rating or a short review on Apple Podcasts or Spotify is how the next listener finds the show — and following it in your app means the next episode is there when you are. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.
    続きを読む 一部表示
    8 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません